# A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

> **NCT03161093** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 3307 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **DRUG:** Fasinumab
- **DRUG:** Naproxen
- **DRUG:** Fasinumab-matching placebo
- **DRUG:** Naproxen-matching placebo

## Key facts

- **NCT ID:** NCT03161093
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2019-09-09
- **Final completion:** 2021-08-27
- **Target enrollment:** 3307 (ACTUAL)
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161093, "A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03161093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*